DFX Intelligence

Shelley Chu

Partner // USat Ashwood Capital Management Ltd· Lexington, MA

As of 2026-10-01 · this person's identity; each section below carries its own date

Current roles: 1
Investments attributed: 2
Board seats: 6

Ask DFX about this View relationships Find contacts Investments Board seats

As of 2026-10-01 · this person's identity; each section below carries its own date

3 additional roles and seats

Every relationship, signal and contact on this record, with the source on each.

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

What matters now

1 deal
12 months
1 investment attributed in the last 12 months; latest Protego Biopharma Form D equity offering ($32.9M) on 3 Dec 2025.
A partner with a recent deal is actively writing cheques now.
Factfunding announcements and Form D naming the personFor Founders, co-investorsInvestments →
6 boards
seats on record
Sits on 6 boards on record, the latest Triana Biomedicines on 4 Dec 2025.
Board seats show where this partner holds governance, not only a cheque.
FactForm D directors and board-seat attributionsFor Founders, co-investorsBoard seats →
Current
role
Partner // US at Ashwood Capital Management Ltd.
Tenure says how settled this partner is at the firm.
FactForm ADV Schedule A and the firm's team pageFor Founders, LPsRoles →

Relationship network

9 connected entities2 observed investment recordsinvestment records 2021 to 2025

From the roles sources name this person in, the investments a source attributes to them, and the boards and funds Form D names them on.

Some relationships on this record are counted rather than named here. They open with the full profile.

Click any name or line for the investment records and sources behind it. Line weight is investment records together; dashed lines are inferred.

Reading the network

Organization
Company
Fund or vehicle

›How strength and recency are read

Venture relationships are not scored. Each line names its claim: a round led or joined, a board seat or a filing that names the firm, a listing on a portfolio page (dated by when DFX saw it, never by when the investment was made), a disclosed LP commitment, or a co-investor pair counted from observed participations. Observed means a named source says so; Derived means DFX counted it from observed rows; Inferred means a match that may be wrong.

Darker lines were active in the last 24 months or are current; lighter lines are older or undated.

Ask DFX about this network

Which companies and boards is Shelley Chu connected to?

How am I connected?

Name your firm, a company or a person, and DFX finds the published routes to Shelley Chu: a shared portfolio company or board, a prior employer, a co-investor, a shared LP or service provider. Every step is a filed or published record with its source; none is a guess about who knows whom.

See how you connect to Shelley Chu

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

Drawing the relationship network…

Roles

2 current, 0 past

Ashwood Capital Management Ltd Partner // US
? to present · “team page: Dr. Shelley Chu / Partner // US”
Fact Firm website
Lightspeed Venture Partners Partner // US
? to present · “team page: Dr. Shelley Chu / Partner // US”
Fact Firm website

Investments attributed to this person

Company	Round	Investor	Attribution	Date	Source
Protego Biopharma, Inc.	Form D equity offering · $32.9M	Ashwood Capital Management Ltd	strongly supported · board	Dec 3, 2025	Inference sec.gov
Protego Biopharma, Inc.	Form D equity offering · $51.0M	Ashwood Capital Management Ltd	strongly supported · board	Oct 28, 2021	Inference sec.gov

Board seats and vehicles

6 boards, 1 vehicle

Triana Biomedicines, Inc. Director Dec 4, 2025 Fact
Protego Biopharma, Inc. board seat on a deal Dec 3, 2025 Inference
Antares Therapeutics, Inc. Director May 15, 2025 Fact
Abingworth Bioventures VII LP Promoter Nov 15, 2016

Timeline

2 dated entries: events, attributed deals, board seats and role changes

Dec 3, 2025
Form D equity offering in Protego Biopharma, Inc. (Ashwood Capital Management Ltd)
Attributed investment Inference Protego Biopharma, Inc. Form D
Oct 28, 2021
Form D equity offering in Protego Biopharma, Inc. (Ashwood Capital Management Ltd)
Attributed investment Inference Protego Biopharma, Inc. Form D

Record history

1 identity change on the change ledger, latest event first

Merged in
2026-10-01

The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.